Goserelin
- Generic Name
- Goserelin
- Brand Names
- Zoladex
- Drug Type
- Small Molecule
- Chemical Formula
- C59H84N18O14
- CAS Number
- 65807-02-5
- Unique Ingredient Identifier
- 0F65R8P09N
- Background
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
- Indication
Goserelin is indicated for:
- Associated Conditions
- Abnormal Uterine Bleeding, Advanced Breast Cancer, Endometriosis, Advanced carcinoma of the prostate, Stage T2b carcinoma of the prostate, Stage T4 carcinoma of the prostate
- Associated Therapies
- Palliative Treatment
Study of Efficacy and Safety in Premenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer
- Conditions
- Advanced Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 672
- Registration Number
- NCT02278120
- Locations
- 🇺🇸
Penn State University Milton S Hershey Medical Center, Hershey, Pennsylvania, United States
🇺🇸Danbury Hospital SC, Danbury, Connecticut, United States
🇺🇸University Of California Los Angeles Dept of Onc, Los Angeles, California, United States
Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer
- Conditions
- Stage III Prostate CancerRecurrent Prostate CancerAdenocarcinoma of the ProstateStage IV Prostate Cancer
- Interventions
- First Posted Date
- 2014-10-29
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 19
- Registration Number
- NCT02278185
- Locations
- 🇺🇸
University of Colorado Health - Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Adjuvant Toremifene With or Without Goserrelin in Premenopausal Women With Stage I-IIIA, Hormonal Receptor Positive Breast Cancer Accompanied With or Without Chemotherapy Induced Amenorrhoea
- Conditions
- Breast CancerChemotherapy Induced AmenorrheaOvarian Function Suppression
- Interventions
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02132390
- Locations
- 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast AdenocarcinomaHER2/Neu NegativeLocally Advanced Breast CarcinomaMetastatic Breast CarcinomaRecurrent Breast Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyDrug: EntinostatDrug: ExemestaneDrug: GoserelinDrug: Goserelin AcetateProcedure: Magnetic Resonance ImagingOther: Placebo AdministrationOther: Quality-of-Life Assessment
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 608
- Registration Number
- NCT02115282
- Locations
- 🇺🇸
University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
🇺🇸NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro, Jonesboro, Arkansas, United States
🇺🇸Mercy San Juan Medical Center, Carmichael, California, United States
The Study of Goserelin Plus Fulvestrant Comparing With Goserelin Plus Anastrozole for Advanced Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2014-02-26
- Lead Sponsor
- Hospital Affiliated to Military Medical Science, Beijing
- Target Recruit Count
- 180
- Registration Number
- NCT02072512
- Locations
- 🇨🇳
307 Hospital, Beijing, Beijing, China
A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 72
- Registration Number
- NCT02059213
- Locations
- 🇺🇸
Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸University of Michigan Hospital, Ann Arbor, Michigan, United States
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer
- Conditions
- HER2-Positive Breast CarcinomaStage IIB Breast Cancer AJCC v6 and v7Stage IIIB Breast Cancer AJCC v7Stage IIIC Breast Cancer AJCC v7Hormone Receptor-Positive Breast CarcinomaStage IIIA Breast Cancer AJCC v7Stage IB Breast Cancer AJCC v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- Drug: Aromatase Inhibition TherapyDrug: CarboplatinOther: Cytology Specimen Collection ProcedureDrug: DocetaxelDrug: Goserelin AcetateBiological: PertuzumabOther: Laboratory Biomarker AnalysisOther: Quality-of-Life AssessmentRadiation: Whole Breast IrradiationProcedure: Therapeutic Conventional SurgeryBiological: Trastuzumab
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 315
- Registration Number
- NCT02003209
- Locations
- 🇺🇸
Ochsner Medical Center Kenner, Kenner, Louisiana, United States
🇺🇸Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States
🇺🇸Allegiance Health, Jackson, Michigan, United States
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer
- First Posted Date
- 2013-10-17
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 234
- Registration Number
- NCT01964170
Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer
- Conditions
- Estrogen Receptor PositiveStage IIA Breast CancerStage IIIB Breast CancerHER2/Neu NegativeStage IIB Breast CancerRecurrent Breast CarcinomaStage IIIC Breast CancerStage IIIA Breast Cancer
- Interventions
- Drug: Akt Inhibitor MK2206Drug: AnastrozoleDrug: Goserelin AcetateOther: Laboratory Biomarker AnalysisProcedure: Neoadjuvant TherapyOther: Pharmacological StudyProcedure: Therapeutic Conventional Surgery
- First Posted Date
- 2013-01-25
- Last Posted Date
- 2018-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 16
- Registration Number
- NCT01776008
- Locations
- 🇺🇸
University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.